Kristina Burow
Kristina Burow's purchase track record
How the stock did after each of Kristina Burow's open-market purchases, measured from the purchase date. Several fills within a week count as one purchase.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 10/27/2025 | NMRA | $5.00M | -24.2% | -17.5% | +4.3% |
| 4/2/2024 | BOLD | $3.20M | -68.4% | -76.1% | +9.7% |
| 11/13/2023 | NMRA | $412K | +51.0% | -25.1% | +18.4% |
| 11/3/2023 | NMRA | $2.64M | +29.6% | -21.9% | +17.6% |
| 9/27/2023 | NMRA | $1.35M | +51.4% | +6.7% | +22.8% |
| 9/19/2023 | NMRA | $27.03M | +21.4% | +17.1% | +16.5% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 15, 2026
NMRA noted among top stock movers today. NMRA appeared in today's list of top stock movements, reflecting notable price activity. The stock is currently trading near its support level of $1.60 and shows a low RSI, suggesting oversold conditions. Analyst consensus target remains at $6.14, well above the current price range.
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 29, 2026
BOLD trades near support amid sector news. Recent headlines focus on Beam Therapeutics and Callio Therapeutics rather than direct developments for Boundless Bio. The stock is currently trading near its identified support level, with technical indicators showing a breakdown signal. Analysts maintain a single price target of $4.00, which sits above the current trading range.
Transaction History
| SRRK | ▼ Sell | Open Market | 2,105 | $113K | 7/1/2026 | View on chart |
| SRRK | ▼ Sell | Open Market | 948 | $51K | 7/1/2026 | View on chart |
| SRRK | ▲ Buy | Grant | 6,839 | $0 | 6/4/2026 | View on chart |
| SRRK | ▲ Buy | Option Exercise | 7,800 | $209K | 4/23/2026 | View on chart |
| SRRK | ▲ Buy | Option Exercise | 28,000 | $133K | 4/23/2026 | View on chart |
| SRRK | ▲ Buy | Option Exercise | 18,000 | $150K | 4/23/2026 | View on chart |
| SRRK | ▲ Buy | Option Exercise | 36,000 | $328K | 4/23/2026 | View on chart |
| NMRA | ▲ Buy | Open Market | 1,915,700 | $5.0M | 10/27/2025 | View on chart |
| SRRK | ▼ Sell | Open Market | 1,000 | $29K | 5/29/2025 | View on chart |
| SRRK | ▼ Sell | Open Market | 4,400 | $131K | 5/29/2025 | View on chart |
| SRRK | ▲ Buy | Grant | 7,632 | $0 | 5/22/2025 | View on chart |
| SRRK | ▲ Buy | Grant | 13,500 | $0 | 6/27/2024 | View on chart |
| NMRA | ▲ Buy | Grant | 20,100 | $0 | 6/13/2024 | View on chart |
| BOLD | ▼ Sell | Other | 589,743 | — | 4/2/2024 | View on chart |
| BOLD | ▼ Sell | Other | 787,545 | — | 4/2/2024 | View on chart |
| BOLD | ▼ Sell | Other | 1,048,433 | — | 4/2/2024 | View on chart |
| BOLD | ▲ Buy | Open Market | 66,667 | $1.1M | 4/2/2024 | View on chart |
| BOLD | ▲ Buy | Open Market | 133,333 | $2.1M | 4/2/2024 | View on chart |
| SRRK | ▼ Sell | Other | 291,906 | $0 | 12/21/2023 | View on chart |
| SRRK | ▼ Sell | Other | 5,339 | $0 | 12/21/2023 | View on chart |
| NMRA | ▼ Sell | Other | 13,997 | — | 12/8/2023 | View on chart |
| NMRA | ▼ Sell | Other | 1,176,593 | — | 12/8/2023 | View on chart |
| NMRA | ▼ Sell | Other | 703,061 | — | 12/8/2023 | View on chart |
| NMRA | ▲ Buy | Open Market | 3,357 | $40K | 11/14/2023 | View on chart |
| NMRA | ▲ Buy | Open Market | 31,653 | $372K | 11/13/2023 | View on chart |
| NMRA | ▲ Buy | Open Market | 11,844 | $135K | 11/10/2023 | View on chart |
| NMRA | ▲ Buy | Open Market | 5,431 | $64K | 11/10/2023 | View on chart |
| NMRA | ▲ Buy | Open Market | 31,079 | $327K | 11/9/2023 | View on chart |
| NMRA | ▲ Buy | Open Market | 69,127 | $745K | 11/8/2023 | View on chart |
| NMRA | ▲ Buy | Open Market | 23,124 | $273K | 11/8/2023 | View on chart |
| NMRA | ▲ Buy | Open Market | 30,192 | $347K | 11/7/2023 | View on chart |
| NMRA | ▲ Buy | Open Market | 43,082 | $498K | 11/6/2023 | View on chart |
| NMRA | ▲ Buy | Open Market | 22,420 | $255K | 11/3/2023 | View on chart |
| NMRA | ▲ Buy | Open Market | 34,560 | $483K | 9/29/2023 | View on chart |
| NMRA | ▲ Buy | Open Market | 16,841 | $220K | 9/28/2023 | View on chart |
| NMRA | ▲ Buy | Open Market | 25,110 | $344K | 9/28/2023 | View on chart |
| NMRA | ▲ Buy | Open Market | 24,504 | $302K | 9/27/2023 | View on chart |
| NMRA | ▲ Buy | Open Market | 34,000 | $399K | 9/26/2023 | View on chart |
| NMRA | ▲ Buy | Open Market | 30,773 | $332K | 9/25/2023 | View on chart |
| NMRA | ▲ Buy | Open Market | 29,967 | $349K | 9/25/2023 | View on chart |
| NMRA | ▲ Buy | Open Market | 40,000 | $446K | 9/22/2023 | View on chart |
| NMRA | ▼ Sell | Other | 13,620 | — | 9/19/2023 | View on chart |
| NMRA | ▼ Sell | Other | 684,167 | — | 9/19/2023 | View on chart |
| NMRA | ▼ Sell | Other | 1,144,973 | — | 9/19/2023 | View on chart |
| NMRA | ▼ Sell | Other | 6,895,021 | — | 9/19/2023 | View on chart |
| NMRA | ▲ Buy | Open Market | 1,500,000 | $25.5M | 9/19/2023 | View on chart |
| NMRA | ▼ Sell | Other | 2,124,143 | — | 9/19/2023 | View on chart |
| NMRA | ▼ Sell | Other | 6,576,400 | — | 9/19/2023 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 8, 2026
Scholar Rock Refiles Apitegromab Application With EMA
Scholar Rock has resubmitted its marketing authorization application to the European Medicines Agency for apitegromab, a treatment for spinal muscular atrophy in children and adults. This regulatory step follows the company's recent release of its Q2 2026 financial results. The stock is currently trading near its 52-week low, which provides context for the significance of this regulatory update.
Scholar Rock Refiles Apitegromab Application With EMA. Scholar Rock has resubmitted its marketing authorization application to the European Medicines Agency for apitegromab, a treatment for spinal muscular atrophy in children and adults. This regulatory step follows the company's recent release of its Q2 2026 financial results. The stock is currently trading near its 52-week low, which provides context for the significance of this regulatory update.